Procarbazine (Matulane)
General information
Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Central nervous system (CNS) cancer
- CNS lymphoma
- Follicular lymphoma
- Hodgkin lymphoma
- Mantle cell lymphoma
Patient drug information
- Procarbazine (Matulane) patient drug information (Chemocare)[3]
- Procarbazine (Matulane) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/22/1969: Initial FDA approval
Also known as
Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine, procarbazine HCl Chugaigai, procarbazine hydrochloride
References
- Drug index
- Chemotherapy
- Oral chemotherapy
- Alkylating agents
- DNA synthesis inhibitors
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Follicular lymphoma medications
- Hodgkin lymphoma medications
- Mantle cell lymphoma medications
- Drugs FDA approved in 1969
- WHO Essential Cancer Medicine